Zhao TT, et al. - Experts pursued an analysis of the efficacy and safety of targeted agents for the treatment of advanced gastric cancer (AGC) patients. An improvement was disclosed in the patient progression-free survival (PFS) and overall survival (OS) due to apatinib, regorafenib, and rilotumumab. It was noted that ramucirumab and rilotumumab, when combined with chemotherapy, illustrated high efficacy but low tolerability. On the other hand, bevacizumab reported moderate efficacy and tolerability for PFS. Findings indicated that without chemotherapy, ramucirumab and regorafenib presented with relatively high therapeutic efficacy tolerability for PFS.